Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Publication date: June 2020Source: The Lancet HIV, Volume 7, Issue 6Author(s): Chloe Orkin, Edwin DeJesus, Paul E Sax, Jose R Arribas, Samir K Gupta, Claudia Martorell, Jeffrey L Stephens, Hans-Jurgen Stellbrink, David Wohl, Franco Maggiolo, Melanie A Thompson, Daniel Podzamczer, Debbie Hagins, Jason A Flamm, Cynthia Brinson, Amanda Clarke, Hailin Huang, Rima Acosta, Diana M Brainard, Sean E Collins
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research